Tajikistan Registration Certificate Holder Obligations: Quality, Efficacy and Safety Duties under Law No. 1893
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Tajikistan assigns the three responsibilities of quality, efficacy and safety for registered products explicitly to the registration certificate holder. Article 17(6) of Law No. 1893 provides that the registration certificate holder bears responsibility for the quality, efficacy and safety of the registered materials. GRZAN notes that this allocation of responsibility carries two implications. First, the responsible party is the registration certificate holder rather than the manufacturer or the applicant. Second, the three responsibilities are continuing obligations that run through the entire five-year validity period and are implemented through three mechanisms: pharmacovigilance under Article 20, withdrawal from circulation under Article 21, and compensation for damage under Article 47. For foreign manufacturers entering Tajikistan, understanding who actually carries these duties is the starting point of every compliance architecture, because these duties cannot be delegated by contract and follow the certificate wherever it sits.
2. Legal basis
| Item | Content |
|---|---|
| Legal basis | Law of the Republic of Tajikistan on Medicines, Medical Devices and Pharmaceutical Activity No. 1893 of July 19, 2022 (re-enacted by Law No. 2181 of May 14, 2025) |
| Responsibility clause | Article 17(6): the registration certificate holder bears responsibility for the quality, efficacy and safety of the registered materials |
| Validity period | Article 17(6): the registration certificate is valid for five years |
| Quality requirement | Article 15(1): medicines, medical devices and parapharmaceuticals must be of high quality, effective and safe, and must comply with the general provisions of pharmacopoeias, the State Pharmacopoeia, quality control normative documents and other standards |
| Vigilance obligation | Article 20(2): subjects of medical and pharmaceutical activity and registration certificate holders conduct pharmacovigilance of medicines and medical devices and monitor their safety, quality and efficacy |
| Reporting obligation | Article 20(3): manufacturers, registration certificate holders of medicines and medical devices, and medical and pharmaceutical professionals must report discovered side effects to the supervisory authority |
| Concealment liability | Article 20(4): concealment of side effects, incomplete reporting and failure to take necessary measures entail liability under the law |
| Market withdrawal | Article 21(1): twelve statutory grounds for withdrawal from circulation |
| Damage compensation | Article 47(1): the manufacturer compensates for damage caused by a substandard product used for its intended purpose, or by inaccurate information in the instructions for use |
3. Expert insights
Insight 1: The party named in Article 17(6) and the parties named in Article 20(2) and (3) are essentially the same group of people, but the wording differs. Article 17(6) uses the term registration certificate holder; Article 20(2) uses subjects of medical and pharmaceutical activity and registration certificate holders; Article 20(3) uses manufacturers, registration certificate holders, and medical and pharmaceutical professionals. The differences in wording show that responsibilities and obligations are allocated by role, and the certificate holder always holds a place among them. GRZAN handles this in entity design by positioning the certificate holder as the core node of responsibilities and obligations, with the manufacturer and local service providers as coordinating nodes.
Insight 2: The three responsibilities correspond one-to-one with the requirements of Article 15(1), forming a closed loop. Article 15(1) requires products to be of high quality, effective and safe; Article 17(6) makes the certificate holder responsible for quality, efficacy and safety. The legal effect of this correspondence is that product standards are converted into statutory duties of the certificate holder. Once a product falls short in any of the three dimensions, responsibility arises immediately, without any further argument.
Insight 3: The continuing nature of the responsibility is reinforced by the cross-border information linkage in Article 20(5). Article 20(5) provides that the supervisory authority, when making decisions on registration, re-registration, suspension and prohibition of use, takes into account vigilance and monitoring information obtained both domestically and abroad. The implication is that the responsibility of the certificate holder is not limited to performance inside Tajikistan; safety data from anywhere in the world can become a basis for determining responsibility. GRZAN recommends making the collection of global vigilance data a standing function of the certificate holder rather than an occasional project task.
Insight 4: Article 47(1) designates the manufacturer as the first-order liable party for damage compensation, forming a second line of responsibility distinct from the certificate holder under Article 17(6). Article 47(1) provides that where damage is caused by a substandard product used for its intended purpose, or by inaccurate information in the instructions for use, the manufacturer pays compensation. This runs in parallel with the administrative line of Article 17(6): administrative responsibility looks to the certificate holder (Article 17(6)), while civil compensation looks to the manufacturer (Article 47(1)). When designing the corporate structure, both lines must be considered together; a company cannot defend only one of them.
Insight 5: The responsibility cannot be transferred through internal agreements, but internal recourse can be agreed. The statutory responsibility under Article 17(6) is allocated to the certificate holder as a matter of public law and cannot be set up against the competent authorities through an agreement between the manufacturer and the holder. GRZAN handles this by agreeing internal recourse mechanisms and information notification duties in the contract, so that risk is kept within a practically manageable range while the statutory allocation remains untouched.
4. Practical recommendations
- Design the structure with the certificate holder as the core node of responsibilities and obligations. Under Article 17(6) and Article 20(2) and (3), determine the registration certificate holder as the core bearer of the quality, efficacy and safety responsibilities and of the vigilance reporting obligations, with the manufacturer and local service providers as coordinating parties.
- Implement the three responsibilities in the quality system as a traceable responsibility matrix. Break the responsibilities for quality, efficacy and safety into concrete processes: change control, complaint handling, vigilance reporting and periodic review, and appoint a responsible person and a backup for each item.
- Make the collection of global vigilance data a standing function of the certificate holder. Under Article 20(5), information obtained abroad influences Tajik decisions on registration and market withdrawal; establish a mechanism for periodic collection and assessment of global safety data.
- Design the internal arrangements for the administrative and civil lines separately. Under Article 17(6) (administrative responsibility of the holder) and Article 47(1) (civil compensation by the manufacturer), agree information notification duties and internal recourse mechanisms between the manufacturer and the certificate holder.
- State clearly that agreements cannot override statutory responsibility. Record in the internal agreement that both parties understand the responsibility under Article 17(6) to be a statutory responsibility and that the agreement produces internal effect only between the two parties.
5. Verification checklist
- □ Confirmed that the responsible party under Article 17(6) is the registration certificate holder
- □ Implemented the quality, efficacy and safety responsibilities as a responsibility matrix in the quality system
- □ Established a mechanism for periodic collection and assessment of global vigilance data (Article 20(5))
- □ Designed internal arrangements separately for administrative responsibility (Article 17(6)) and civil compensation (Article 47(1))
- □ Recorded in internal agreements that statutory responsibility cannot be overridden by agreement
- □ Confirmed that owners are appointed for the vigilance and reporting duties under Article 20(2) and (3)
- □ Established continuous monitoring indicators for the three product attributes under Article 15(1)
Regulatory information verified as of October 29, 2026.
In the Central Asian market, the core capabilities of GRZAN focus on three points. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a choice exists between a national pathway and a Union pathway; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan are outside the Union framework and must follow purely national procedures. Second, local authorised representative services: GRZAN can act as the statutory representative of manufacturers in the above countries, undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN assists in establishing a quality management system conforming to ISO 13485 and connects clients with locally accredited laboratory resources.
For business inquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us